The complaint filed by Robbins LLP represents investors who purchased Embecta securities between November 25, 2025, and May 4, 2026. According to the filing, the company's management maintained optimistic revenue projections throughout this window, specifically touting the strength of its core diabetes-focused product lines. These assurances reportedly collapsed on May 5, 2026, when Embecta disclosed a 14% revenue decline—far exceeding previous forecasts of a flat result or a 2% dip.

The disclosure prompted a significant market correction, with shares sliding to $3.90. The lawsuit claims these missed targets were tied directly to hidden weakness in the company’s U.S. pen needle segment, which had been presented to investors as a pillar of stability. Shareholders seeking to serve as lead plaintiff or recover losses must contact Robbins LLP, which is handling the case on a contingency fee basis.